Keep up to date with all of the latest company news, press releases and updates.

News_
CHARM Therapeutics announces first patient dosed and first cohort fully enrolled in its Phase I/II clinical trial of CHM-029 for Acute Myeloid Leukemia
October 7, 2026

CHARM Therapeutics announces first patient dosed and first cohort fully enrolled in its Phase I/II clinical trial of CHM-029 for Acute Myeloid Leukemia

Read More
CHARM Therapeutics announces formation of Clinical Advisory Board to support advancement of CHM-029, its next-generation menin inhibitor
August 18, 2026

CHARM Therapeutics announces formation of Clinical Advisory Board to support advancement of CHM-029, its next-generation menin inhibitor

Read More
CHARM Therapeutics advances CHM-029, a next-generation menin inhibitor designed to overcome resistance mutations, as its first clinical candidate for acute myeloid leukaemia (AML)
November 13, 2025

CHARM Therapeutics advances CHM-029, a next-generation menin inhibitor designed to overcome resistance mutations, as its first clinical candidate for acute myeloid leukaemia (AML)

Read More
CHARM Therapeutics Appoints Dr Erkut Bahceci as Chief Medical Officer
September 8, 2025

CHARM Therapeutics Appoints Dr Erkut Bahceci as Chief Medical Officer

Read More
CHARM Therapeutics raises $80 million in Series B financing to advance development of best-in-class menin inhibitor for AML
September 2, 2025

CHARM Therapeutics raises $80 million in Series B financing to advance development of best-in-class menin inhibitor for AML

Read More
CHARM Therapeutics appoints Dr Beverley Carr as Chief Business Officer
September 10, 2024

CHARM Therapeutics appoints Dr Beverley Carr as Chief Business Officer

Read More
CHARM Therapeutics appoints Dr Nicholas Edmunds as Chief Development Officer, Head of Pre-Clinical Development
April 30, 2024

CHARM Therapeutics appoints Dr Nicholas Edmunds as Chief Development Officer, Head of Pre-Clinical Development

Read More

Transforming outcomes for patients living with AML